Open Innovation Practices and Open Innovation Culture in the Life-Sciences Clusters. The Case of AstraZeneca



Abstract Views
1631

Downloads
1708

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Dec 13, 2021
Published Jan 19, 2022
10.24018/ejbmr.2022.7.1.1201

Abstract viewed = 1631 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

The study contributes to the emerging debate on the open innovation ecosystems by sharing insights and knowledge on the open innovation practices in life sciences sector, using the example of Cambridge cluster and its linkages with AstraZeneca. The authors applied descriptive data analysis and case study method. The study shows that decentralisation of corporate R&D process and investments into building an open innovation culture enabled AstraZeneca to exploit its local knowledge and information more effectively. The example of AstraZeneca allows to understand better the phenomenon of open innovation and shares some of the open innovation instruments, which could be adopted by other firms.

Keywords: Cambridge, Life-sciences, Open Innovation, University, AstraZeneca

Downloads

Download data is not yet available.

References

  1. Uthman, Arocena, R., Goransson, B., Sutz, J. (2018), Developmental Universities in Inclusive Innovation Systems. Alternatives for Knowledge Democratization in the Global South, Palgrave Macmillan.
     Google Scholar
  2. ADNER, R. (2016), Ecosystem as Structure: An Actionable Construct for Strategy. Journal of Management, 43(1).
     Google Scholar
  3. AstraZeneca R&D expenditure 2006-2020 | Statista (2021). Available at: https://www.statista.com/statistics/266556/expenditure-on-research-and-development-of-astrazeneca-since-2006/ (Accessed: 16 June 2021).
     Google Scholar
  4. Atterfors H. and Farneman, S. (2012), The Role of Open Innovation: Focus on the Pharmaceutical Industry. p. 68. Available at: https://azcollaboration.sharepoint.com/sites/ Innovation/Study of OI in AZ.pdf.
     Google Scholar
  5. Backer, K.D. (2008), Open Innovation In A Global Perspective: What do existing data tell us?, OECD: Paris.
     Google Scholar
  6. Blumenthal, D., Campbell, E.G., Causino, N. (1996), Participation of life-science faculty in research relationships with industry, New England Journal of Medicine, 335, 1734-1739.
     Google Scholar
  7. Business and enterprise, University of Cambridge (2021). Available at: https://www.cam.ac.uk/business-and-enterprise (Accessed: 13 June 2021).
     Google Scholar
  8. Chesbrough, H. W. (2003) Open Innovation the New Imperative for Creating and Profiting from Technology.
     Google Scholar
  9. Clinical Trials | PhRMA (2021). Available at: https://www.phrma.org/Advocacy/Research-Development/Clinical-Trials (Accessed: 16 June 2021).
     Google Scholar
  10. Home | Cambridge Consultants (2021). Available at: https://www.cambridgeconsultants.com/home (Accessed: 13 June 2021).
     Google Scholar
  11. Brocke, J., Lippe, S. (2015), Managing collaborative research projects: A synthesis of project management literature and directive for future research, International Journal of Project Management, 33(5).
     Google Scholar
  12. Chesbrough, H., (2003), Open Innovation: The New Imperative for Creating and Profiting from Technology. Boston: Harvard Business School Press.
     Google Scholar
  13. Chesbrough, H. (2006), Open innovation: A new paradigm for understanding industrial innovation. In H. Chesbrough, W. Vanhaverbeke, J. West, (Eds), Open innovation: Researching a new paradigm, Oxford: Oxford University Press, 1-12.
     Google Scholar
  14. Chesbrough, H., Crowther, A.K. (2006), Beyond high tech: Early adopters of open innovation in other industries, Journal of R&D Management, 36 (3), 229-236.
     Google Scholar
  15. Dhanaraj, C., Parkhe, A. (2006), Orchestrating Innovation Networks, Academy of Management Review, 31(3), 659–669.
     Google Scholar
  16. Hertzog, P., Leker, J. (2010), Open and closed innovation – different innovation cultures for different strategies, International Journal of Technology Management, 52 (3-4), 322-343.
     Google Scholar
  17. Fasnacht, D. (2018), Open Innovation Ecosystems: Creating New Value Constellations in the Financial Services, In: Open Innovation Ecosystems, 5, Springer, 131-172. https://www.researchgate.net/publication/329037798.
     Google Scholar
  18. Kozierkiewicz, B. (2020), Life Sciences Clusters in Poland: Drivers, Structure and Challenges.
     Google Scholar
  19. In: Runiewicz-Wardyn, M. (Ed.) Social Capital in the University-Based Innovation Ecosystems in the Leading Life-Science Clusters: Implications for Poland, Warszawa. Poltext.
     Google Scholar
  20. Krause, W., Schutte, C., DU Preez, N. (2012), Open Innovation in South African Small and Medium-Sized Enterprises, Proceedings of the International Conference on Computers & Industrial Engineering (CIE42), Cape Town, South Africa, CIE & SAIIE 2012, 201-210.
     Google Scholar
  21. Laursen K., Salter, A. (2006), Open for Innovation: The Role of Openness in Explaining Innovation Performance Among U.K. Manufacturing Firms, Strategic Management Journal, 27(2), 131–150.
     Google Scholar
  22. Gasmann, O, Enkel, E, Chesbrough, H (2010), The Future of Open Innovation. Blackwell Publishing Ltd. Open Innovation 2.0, European Commission, https://ec.europa.eu/digital-single-market/en/open-innovation-20
     Google Scholar
  23. Pomponi, F, Tafuri, S., Fratocchi, L. (2015), Trust development and horizontal collaboration in logistics: A theory based evolutionary framework, Supply Chain Management, 20(1).
     Google Scholar
  24. Runiewicz-Wardyn, M. (2020), Social Capital in the University-Based Innovation Ecosystems in the Leading Life-Science Clusters: Implications for Poland, Warszawa. Poltext.
     Google Scholar
  25. Runiewicz-Wardyn, M. (2016), Innovations and Emerging Technologies for the Prosperity and Quality of Life, Warsaw, PWN.
     Google Scholar
  26. Runiewicz-Wardyn, M. (2013), Knowledge Flows, Technological Change and Regional Growth in the European Union, Contributions to Economics, Springer.
     Google Scholar
  27. Roper S., Vahterb P., Lovec, J. H. (2013), Externalities of openness in innovation, “Research Policy”, Volume 42, Issue 9, November 2013, 1544-1554.
     Google Scholar
  28. Stenninger, S. (2014), Open Innovation and Barriers to Adoptation: A Case Study in the Construction Industry, Charlmers University of Technology, https://odr.chalmers.se/bitstream/20.500.12380/204671/1/204671.pdf.
     Google Scholar
  29. Sznyk, A., Karasek, J. (2016), Raport innowacyjność w sektorze ochrony zdrowia w Polsce, Warszawa: Instytut Innowacyjna Gospodarka.
     Google Scholar
  30. Trzmielak, D. (2013), Innowacje i komercjalizacja w biotechnologii, Warszawa.
     Google Scholar
  31. Torkelli, M. T., Kock, C. J., Salmi, P. A. (2009), The “Open Innovation” paradigm: A contingency perspective, Journal of Industrial Engineering and Management, 2(1), 176-207
     Google Scholar
  32. Witzeman S., Slowinski, G., Dirkx R., Gollob, L. (2006), Harnessing External Technology for Innovation, Research Technology Management, 49(3), 19-27.
     Google Scholar
  33. Niedergassel, B., Leker J. (2009), Open innovation: chances and challenges for the pharmaceutical industry, Future Medicinal Chemistry, 1(7), 1197–1200.
     Google Scholar
  34. Chesbrough H.W., (2003), Open Innovation: the new imperative for creating and profiting from technology. Harvard Business School Press.
     Google Scholar
  35. AstraZeneca launches ‘Open Innovation’ initiative, Pharmaphorum (2014) Pharmaphorum. Available at:
     Google Scholar
  36. https://pharmaphorum.com/news/astrazeneca-launches-open-innovation-initiative/ (Accessed: 16 June 2021).
     Google Scholar
  37. Medina, C.C., Tijssen, R. (2007). Research cooperation within the bio-pharmaceutical industry: Network analyses of co-publications within and between firms. Scientometrics.
     Google Scholar
  38. New Cambridge Center to connect AI, medicine and life sciences sector | EurekAlert! Science News (2020). Available at: https://www.eurekalert.org/pub_releases/2020-11/uoc-ncc111120.php (Accessed: 16 June 2021).
     Google Scholar
  39. Osbourn, J. (2018), AstraZeneca: building a new “open innovation” pharma company, PMLiVE. Available at: http://www.pmlive.com/pharma_intelligence/AstraZeneca_building_a_new_open_innovation_pharma_company_1255460 (Accessed: 13 June 2021).
     Google Scholar
  40. Research, University of Cambridge (2021). Available at: https://www.cam.ac.uk/research (Accessed: 13 June 2021).
     Google Scholar
  41. Schuhmacher, A. (2018) Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?, Journal of Translational Medicine. BioMed Central Ltd. doi: 10.1186/s12967-018-1499-2.
     Google Scholar
  42. Staton, T. (2015), Merck tallies 36,000 job cuts in 5 years of restructuring, FiercePharma. Available at:
     Google Scholar
  43. https://www.fiercepharma.com/corporate/merck-tallies-36-000-job-cuts-5-years-of-restructuring (Accessed: 16 June 2021).
     Google Scholar
  44. Strategic partner: AstraZeneca (2021). Available at: https://www.cam.ac.uk/business/astrazeneca (Accessed: 13 June 2021).
     Google Scholar
  45. Trinity College Cambridge, University of Cambridge (2021), Available at: https://www.trin.cam.ac.uk/ (Accessed: 13 June 2021).
     Google Scholar